

1 **Title:** Prevalence of SARS-CoV-2 among high-risk populations in Lomé
2 (Togo) in 2020.
3

4 **Authors:**

5 Wemboo Afiwa HALATOKO ^{1¶}, Yao Rodion KONU ^{2,3¶*}, Fifonsi Adjidossi GBEASOR-
6 KOMLANVI ^{2,3}, Arnold Junior SADIO ^{2,3}, Martin Kouame TCHANKONI ³, Koffi
7 Segbeaya KOMLANVI ³, Mounerou SALOU ^{4,5,6}, Ameyo Monique DORKENOO ^{5,7},
8 Issaka MAMAN ¹, Amétépé AGBOBLI ⁵, Majesté Ihou WATEBA ^{5,6}, Komi Séraphin
9 ADJOH ^{5,6}, Edem GOEH AKUE ^{5,6}, Yem-bla KAO ⁶, Innocent KPETO ⁶, Paul PANA ⁶,
10 Rebecca KINDE-SOSSOU ⁷, Agbeko TAMEKLOE ⁷, Josée NAYO-APETSIANYI ⁷,
11 Simon-Pierre Hamadi ASSANE ⁷, Mireille PRINCE-DAVID ^{4,5}, Sossinou Marcel
12 AWOUSSE ^{7,8}, Mohaman DJIBRIL^{5,8}, Moustafa MIJIYAWA ^{5,7}, Anoumou Claver
13 DAGNRA ^{4,5,6,7&}, Didier Koumavi EKOUEVI ^{2,3, 6,9&}

14

- 15 1. Institut National d'Hygiène (INH), Lomé, Togo
16 2. Université de Lomé, Département de Santé Publique, Lomé, Togo
17 3. Centre Africain de Recherche en Epidémiologie et en Santé Publique
18 (CARESP), Lomé, Togo
19 4. Université de Lomé, Laboratoire de Biologie Moléculaire et d'Immunologie
20 (BIOLIM), Lomé Togo
21 5. Université de Lomé, Faculté des Sciences de la Santé, Lomé, Togo
22 6. Conseil Scientifique pour la Riposte contre la Covid-19, Lomé, Togo
23 7. Ministère de la Santé et de l'Hygiène Publique, Lomé, Togo
24 8. Coordination Nationale de la Lutte contre la Covid-19, Lomé, Togo
25 9. Centre Inserm, 1219, Institut de Santé Publique et de Développement et
26 Université de Bordeaux, Bordeaux, France
27

28 *** Corresponding author**

29 Mail : rodionko@yahoo.fr (YRK)
30

31 ¶ Contributed equally to this work and share primary authorship

32 & Contributed equally to this work and share senior authorship
33

34 Authors details

- 35 • WAH: hjacky78@yahoo.fr
- 36 • YRK: rodionko@yahoo.fr
- 37 • FAGK: fifonsi.gbeasor@gmail.com
- 38 • AJS: sadioarnorld@gmail.com
- 39 • MKT: tchankonimartin@yahoo.fr
- 40 • KSK: komlanvikoffi@yahoo.fr
- 41 • MS: mounerous@gmail.com
- 42 • AMD: monicadork@yahoo.fr
- 43 • IM: mamanissaka@yahoo.fr
- 44 • AA: mag1.tg@gmail.com
- 45 • MIW: majeste7@yahoo.fr
- 46 • KSA: komiadjoh@yahoo.fr
- 47 • EGA: edemcardiol@yahoo.fr
- 48 • YK: yemblak@gmail.com
- 49 • IK: ikpeto@gmail.com
- 50 • PP: assimawepaul@gmail.com
- 51 • RKS: kinderebecca@yahoo.fr
- 52 • AT: stanrameklo@yahoo.fr
- 53 • JNA: jyda45@hotmail.com
- 54 • SHA: simpassane@yahoo.fr
- 55 • MPD: mireilleprincedauid@gmail.com
- 56 • SMA: awoussi@yahoo.com
- 57 • MD: m_djibril2000@yahoo.fr
- 58 • MM: moustafa.mijiyawa@gouv.tg
- 59 • ACD: claverdagnra@gmail.com
- 60 • DKE: didier.ekouevi@gmail.com

61

62

63 **Summary**

64 **Objective:** This survey aims at estimating the prevalence of SARS-CoV-2 in high risk
65 populations in Lomé.

66 **Methods:** From April 23rd to May 8th 2020, we recruited a random sample of
67 participants from five sectors: healthcare, air transport, police, road transport and
68 informal. We collected oropharyngeal swab for direct detection through real time
69 reverse transcription polymerase chain reaction (rRT-PCR), and blood for antibodies
70 detection by serological tests. The overall prevalence (current and past) of infection
71 was defined by positivity for both tests.

72 **Results:** A total of 955 participants with a median age of 36 (IQR 32–43) were included
73 and 71.6% (n=684) were men. Around 22.1% (n=212) were from the air transport
74 sector, 20.5% (n=196) in the police, and 38.7% (n=370) in the health sector. Seven
75 participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR at the time of
76 recruitment and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG
77 against SARS-CoV-2. We found an overall prevalence of 1.6% (n=15), 95% CI: 0.9-
78 2.6%.

79 **Conclusion:** The prevalence of the SARS-CoV-2 infection among high-risk
80 populations in Lomé was relatively low and could be explained by the various
81 measures taken by the Togolese government. Therefore, we recommend targeted
82 screening.

83 **Keywords:** Prevalence, SARS-CoV-2, Covid-19, high-risk populations, rRT-PCR,
84 serology, Togo.

85 **Introduction**

86 In December 2019, an outbreak of pneumonia (Covid-19) due to a new coronavirus
87 first named 2019-nCoV, now officially SARS-CoV-2, occurred in China [1]. In less than
88 five months, this outbreak had spread rapidly to every continent (except Antarctica)
89 with more than 3.7 million people infected and more than 257,000 deaths recorded as
90 of May 8th 2020 in 214 countries and territories [2]. In Africa, 32,953 (0.9%) cases of
91 Covid-19 had been reported as of May 8th 2020 [3].

92

93 Since the beginning of the outbreak, health systems in developed countries have faced
94 many challenges to fight the Covid-19. Numerous assumptions have been made about
95 the true magnitude and evolution of the epidemic around the world. It has been
96 commonly assumed that officially reported data are underestimated [4,5], especially in
97 Africa. Insufficient diagnostic capacity of countries and the high proportion of
98 asymptomatic cases may explain such underestimation [6]. Thus, the World Health
99 Organization (WHO) has recommended a mass screening strategy for all countries
100 burdened by the epidemic with the hypothesis that [7] more tests performed would
101 result in an easier tracking of the spread of the virus and thus a decrease in
102 transmission [8]. However, there is insufficient testing capacity in many countries due
103 to a high global demand for antibody test kits [8] and GeneXpert which has recently
104 been validated by the US Food and Drug Administration [9]. To date, real-time reverse
105 transcription-polymerase chain reaction (rRT-PCR) remains the gold standard test for
106 the diagnosis of Covid-19. Antibodies are the best biomarkers to estimate the number
107 of people previously infected: its use could help estimate the prevalence and inform
108 testing strategies in populations at higher risk of Covid-19.

109

110 In Togo, the first case of Covid-19 was reported on March 5th 2020 and as of April 26th
111 2020, 98 cases were confirmed, including 6 deaths [10]. Only suspect cases, contacts,
112 and travellers were being screened for SARS-CoV-2. The value of population mass
113 screening was debated considering the country's relatively limited diagnostic
114 capabilities. Few studies so far have been conducted to estimate the prevalence of
115 SARS-CoV-2 based on rRT-PCR test or antibody test including studies in Iceland [11],
116 Santa-Clara County in USA [12] and Switzerland [13]. To our knowledge, there is no
117 data available on the prevalence of SARS-CoV-2 in Sub-Saharan Africa. Based on the
118 low incidence of SARS-CoV-2 infection observed in the general population, the Swiss
119 National Covid-19 Science Task Force recommends focusing research at the
120 population level on subpopulations at higher risk of infection [14]. Therefore, we
121 conducted a pilot survey in high risk populations to estimate the prevalence of SARS-
122 CoV-2 using a rRT-PCR test in order to refine screening strategies in the fight against
123 the pandemic in Togo.

124

125

126 **Methods**

127 ***Study design and sampling***

128 A cross-sectional study was conducted by a multi-disciplinary team (demographers,
129 epidemiologists, biologists, biostatisticians) among high-risk populations in Lomé
130 (capital city of Togo) from April 23rd to May 8th, 2020. Participants were recruited from
131 five professional sectors: healthcare (doctors, nurses, pharmacy auxiliaries, hospital
132 administrators), air transport, police, road transport (taxi and moto-taxi drivers) and
133 informal (market sellers and craftsmen). These groups were targeted because they are
134 at high risk of contamination during epidemics for their high probability of being in close
135 contact with travelers or with Covid-19 patients [15,16]. Participants were eligible to
136 participate in the study if the following four criteria were fulfilled: (i) ≥ 18 years of age;
137 (ii) working in one of the five sectors; (iii) having been regularly present at the
138 workstation for the past 30 days; (iv) living in Lomé for the past 3 months.

139 Several sampling methods were used for participants' selection based on the expected
140 total size of the target population and the availability of a sampling frame. First,
141 exhaustive recruitment was performed among the police (road safety officers) and
142 people in air transport (*International Airport Gnassingbe Eyadema, Lomé, Togo*).
143 Second, participants from the informal sector were recruited based on an open
144 invitation. Third, random sampling (two or three stage) was performed for the
145 recruitment of taxi motos (road transport) and health care workers. For example, for
146 the selection of taxi moto drivers we performed a two-stage sampling with the selection
147 of the company, then the selection of the drivers working in the company.

148

149

150 ***Sample size estimation***

151 The sample size was estimated using a single proportion population formula with a
152 95% confidence level, 1% margin of error, and 2% estimated prevalence of SARS-
153 CoV-2 among high risk populations (as defined above) based on surveillance data in
154 travelers in Togo (Ministry of health). A 10% unusable biological specimens or non-
155 response rate was anticipated and the minimum number of participants was estimated
156 at 837.

157 ***Data collection***

158 We established a test site at the 'Faculté des Sciences de la Santé de l'Université de
159 Lomé' (Faculty of medicine, University of Lomé) and invited the target population to
160 join us on site for inclusion. After eligibility screening and written informed consent
161 approval, sociodemographic characteristics and Covid-19 epidemiological data were
162 collected using a standardized questionnaire. The questionnaire was administered by
163 a trained study team (medical doctors) during a face-to-face interview. Oropharyngeal
164 (OP) and blood samples were collected by trained and well-equipped staff of the
165 'Institut National d'Hygiène' (INH) which is the reference laboratory for SARS-CoV-2
166 testing in Togo. Oropharyngeal swabs were collected using Eswab type swabs and
167 samples were tested for SARS-CoV-2 using rRT-PCR at the INH. Whole blood
168 specimens were collected in EDTA tubes to test for anti-SARS-CoV-2 serologic
169 markers at the 'Laboratoire de Biologie Moléculaire et d'Immunologie, Université de
170 Lomé' (BIOLIM).

171

172

173

174 **Laboratory procedures**

175 *Molecular detection of SARS-CoV-2 using TIB MOL BIOL rt RT-PCR Kit*

176 Detection of SARS-CoV-2 in oropharyngeal samples has been performed using
177 molecular biology methods, such as recommended by WHO and US CDC [17,18].

178 The TIB MOLBIOL (Olfert Landt, Berlin Germany) LightMix® SarbecoV E-gene plus
179 EAV control PCR kit and the LightMix® Modular COVID-19 RdRp gene has been used
180 for the amplification and qualitative detection of nucleic acid of SARS-CoV-2.
181 Amplification was carried out after viral RNA extraction using the QIAamp Viral RNA
182 Mini Kit (Qiagen Str, Hilden, Germany). The detection algorithm used was a two-step
183 process involving first a screening assay for sarbecovirus by targeting the E gene to
184 detect both SARS virus and COVID-19 virus; and secondly a confirmation assay for
185 COVID-19 virus only by targeting the RNA dependent RNA polymerase gene (RdRp),
186 specific gene for SARS-CoV-2.

187 Internal quality control was ensured by the use of three controls included in the kit
188 supplied by the company TIB MOL BIOL (Eresburgstr. 22-23 | D-12103 Berlin,
189 Germany). A control during extraction (EAV extraction control, ref. 40-0776-96, TIB
190 MOL BIOL, Germany) to detect possible inhibition of PCR; a positive control for each
191 gene to be detected (positive control of the E gene, ref. 40-0776-96, TIB MOL BIOL,
192 Germany and positive control of the RdRp gene; ref. 53-0777-96, TIB MOL BIOL,
193 Germany) to ensure good performance of the PCR reaction and a negative control (no
194 control model, NTC) to verify the absence of contamination of the reagents. The
195 performance of the test is only accepted if the values of the threshold cycles (Ct) of the
196 positive controls (PTC) of E positive gene control <30; Positive control of RdRp gene

197 <30; Control of the extraction of the EAV <33 and the NTC does not generate any
198 amplification curve.

199 A sample was considered positive if the Ct genes of E <36 and RdRp <40 with the
200 presence or absence of EAV extraction control. If the RdRp gene did not appear or the
201 Ct> 40, the sample was considered probable at Covid-19. A sample was considered
202 negative (below the threshold) if no amplification curve was observed for the E and
203 RdRp genes and the EAV extraction control <33. If, on the other hand, the EAV had
204 no curve, the test was retaliated for the corresponding sample.

205 The INH molecular biology laboratory participated in May 2020 in the external quality
206 control under the supervision of WHO within the framework of its pilot program external
207 quality assessment program (EQAP) for the detection of SARS-CoV-2 virus by RT-
208 PCR.

209 *Detection of SARS-CoV-2 antibodies*

210 Detection of serological markers (Immunoglobulins G and M) of SARS-CoV-2 infection
211 was carried out at BIOLIM using the Lungene® Rapid Test (Hangzhou Clongene
212 Biotech Co, Ltd). The sensitivity and specificity were 72.85% and 85.02%, respectively
213 [19].

214 This test was also validated by Laboratory Department of the ministry of health in Togo.
215 Sensitivity of the assay using samples from participants previously diagnosed with
216 Covid-19 at the day of hospitalization was 77.1% for IgM or IgG and specificity of
217 95.4%. Moreover, the sensitivity was measured 7 days after hospitalization and
218 reported a sensitivity of 93.3% for IgG signing the contact with SARS-CoV-2 [20].

219

220 ***Care and treatment***

221 Biological samples tests results were available within 48 hours. All participants
222 screened positive for SARS-CoV-2 were quarantined in a dedicated hotel or at the
223 national Covid-19 treatment center and those who were tested negative were invited
224 to respect all the mitigation measures proposed by the government.

225

226 ***Statistical analysis***

227 Descriptive statistics were performed and results are presented with frequency
228 tabulations and percentages for categorical variables. Quantitative variables are
229 presented as medians with their interquartile range (IQR). Seroprevalence of
230 antibodies against SARS-CoV-2, prevalence of SARS-CoV-2 infection by rRT-PCR
231 and overall prevalence of past or current infection (positive rRT-PCR or antibody
232 seropositivity) were estimated with their 95% confidence interval (95%CI).
233 Comparisons of categorical variables were performed using chi-square or Fisher's
234 exact tests. Data analyses were performed using R[®] version 3.4.3 software and the
235 level of significance was set at 5%.

236

237 ***Ethical considerations***

238 Ethical approval was obtained from the 'Comité de Bioéthique de Recherche en Santé'
239 (Bioethics Committee for Health Research) from the Togo Ministry of Health (No.
240 004/2020/CBRS). Potential participants were informed about the study purpose and
241 procedures, potential risks and protections. Those willing to participate were invited to
242 sign a consent prior to participation.

243 **Results**

244 **Sociodemographic characteristics**

245 A total of 955 people with a median age of 36 (IQR 32–43) were included in the study
246 and 71.6% (n=684) were men. Approximately 22.1% (n=212) were in the field of air
247 transport, 20.5% (n=196) in the police, 5.8% (n=55) in the informal sector, 38.7%
248 (n=370) in the health sector and 12.8% (n=122) in the road transport sector. None of
249 the participants had been previously diagnosed Covid-19 positive or hospitalized in the
250 last 30 days before the enrolment. The majority of participants, (n=936, 98.0%) were
251 Togolese, around two-thirds (n=636, 66.6%) were in a couple and half (n=487, 51.0%)
252 of them had university level degree. The sociodemographic characteristics according
253 to the sector of activity are summarized in Table 1.

254

255 **Table 1.**

256

257 Participants came from all the five health districts of the city of Lomé as shown in Figure
258 1.

259 **Figure 1**

260

261 **Prevalence of current infection as determined by a positive rRT-PCR**

262 Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR of SARS-CoV-2
263 at the time of recruitment and the prevalence varied from 0% for the participants from
264 the road transport to 1.8% for those in the informal sector of activities. The prevalence
265 was 0.7%, 95% CI [0.3-1.8] in men and 0,7%, 95% CI [0.1-2.8] in women (p=0.683).

266

267

268 **Seroprevalence of antibodies against SARS-CoV-2**

269 Nine participants (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against
270 SARS-CoV-2 (**Table 2 and Figure 2**) and one of them was seropositive for both IgM
271 and IgG. Table 2 summarize the seroprevalence of IgG or IgM according to the sector
272 of activities. Thus, a total of 15 participants (1.6%, 95% CI: 0.9-2.6%) were positive for
273 rRT-PCR or seropositive for IgM or IgG against SARS-CoV-2. This prevalence ranged
274 between 0.8% in the road transport sector and 1.9% in the health sector (Table 2).

275

276 **Table 2 and Figure 2**

277

278 **Clinical manifestations, care and treatment**

279 Six out of seven rRT-PCR positive participants were asymptomatic. The symptomatic
280 participant had presented fever, headaches, and myalgia during the two weeks prior
281 to enrolment. All rRT-PCR positive participants were hospitalized at the national
282 reference center for Covid-19 and treated with hydroxychloroquine and azithromycin
283 as recommended by the national guidelines [21]. Description of the seven rRT-PCR
284 positive participants is presented in Table 3.

285

286 **Table 3**

287

288

289 Discussion

290 To our knowledge, this is the first study reporting the prevalence of SARS-CoV-2 in
291 sub-Saharan-Africa in a representative sample of high-risk populations. The present
292 study was conducted in a context of urgent need for data for decision-making and
293 refinement of response strategies. SARS-CoV-2 prevalence was assessed by
294 molecular biology and serologic tests. In Lomé, capital city of Togo, 2 months after the
295 first case of Covid-19, the prevalence of SARS-CoV-2 infection among persons at high
296 risk for infection was 1.6% based on the presence of antibodies and viral genomes.
297 Using rRT-PCR alone, only 0.7% of the study population was found to be infected with
298 SARS-CoV-2.

299
300 Few studies have focused on high risk populations for Covid-19. In the United States,
301 a screening of an alleged high-risk population of residents and staff members from five
302 homeless shelters was conducted in the cities of Boston, San Francisco, Seattle and
303 Atlanta [22]. This study reported a prevalence of SARS-CoV-2 infection ranging from
304 4 to 66% among residents and 1 to 30% among staff [22]. Healthcare workers (HCWs)
305 are particularly considered as high-risk populations. In a study conducted in United
306 Kingdom (UK), over a 3-week period (April 2020), 1,032 asymptomatic HCWs were
307 screened for SARS-CoV-2 in a large UK teaching hospital. rRT-PCR was used to
308 detect viral RNA from a throat and nose self-swab [23]. Among these asymptomatic
309 HCWs, 3% were tested positive for SARS-CoV-2 [23]. In Lomé, the prevalence among
310 HCWs was 0.5% based on virological test and 1.9% (virological and antibody test), but
311 this included administrative and pharmacy staff.

312

313 Most Covid-19 prevalence surveys have been carried out in the general population. In
314 a survey conducted in Iceland, 1,221 (13.3%) of the 9,199 people who were recruited
315 using the symptom-targeted method were positive for SARS-CoV-2 infection [11].
316 Among those tested by open invitation selection or random selection, SARS-CoV-2
317 prevalence was 0.8% and 0.6%, respectively [11]. In another survey in Santa Clara
318 County, California, USA, the crude prevalence of SARS-CoV-2 antibodies was 1.5%
319 [12]. After weighing for population demographics of Santa Clara County, the
320 prevalence was 2.8% [12]. In Geneva, Switzerland, another study found that the
321 seroprevalence of SARS-CoV-2 in the general population was low (about 5%), despite
322 the high incidence of Covid-19 in Geneva compared with other cantons [13]. All of the
323 studies carried out in the general population based on survey or mathematical model
324 such as in France (4.4%), reported low prevalence of SARV-CoV-2 despite the
325 magnitude of the infection [24].

326
327 Recent evidence highlighted a highest sensitivity of the use of nasopharyngeal
328 samples compared to oropharyngeal ones in rRT-PCR [25]. In a study conducted in
329 China including 353 patients, using both oropharyngeal and nasopharyngeal swabs,
330 SARS-Cov-2 rRt-PCR was positive in 19.0% of nasopharyngeal specimens against
331 7.6% in oropharyngeal [26]. Another survey reported that the SARS-CoV-2 detection
332 rate was significantly higher for nasopharyngeal swabs [46.7% (56/120)] than
333 oropharyngeal swabs [10.0% (12/120)] ($P < 0.001$) [25]. This could certainly contribute
334 to underestimate the prevalence reported in our population. This prevalence could be
335 multiplied by two or three according to available data but remain less than 3%.
336 However, at the time of the survey there was no clear recommendation on which swab

337 to choose. Also, unavailability of nasopharyngeal swabs didn't allow us to collect both
338 specimens.

339
340 The use of serological tests as an effective method for the detection of SARS-CoV-2
341 has been reported previously in the literature. In a study conducted in Wuhan, China,
342 of the 56 enrolled symptomatic patients, 40 (71%) showed negative nucleic acid tests
343 and 16 (29%) were positive. Among the 40 negative patients, 34 (85%) tested positive
344 for the presence of IgM antibodies. Among the 16 patients who tested positive with
345 nucleic acid tests, one patient showed a negative IgM level. The IgG antibody test was
346 positive in all 56 patients [27]. In the present study, the prevalence of SARS-CoV-2
347 increased to 1.6% when serology results were included in the analysis. Based on the
348 validation of the test in Togo and elsewhere, the data reported on serological samples
349 seem reliable. Since serology is rapid and inexpensive it could constitute an attractive
350 screening alternative for countries with limited resources in the context of easing of
351 restrictive measures.

352
353 This study targeted people considered at high risk for Covid-19 based on professional
354 activity as recently recommended by the Swiss National Covid-19 Science Task Force.
355 The WHO also recommends to conduct survey to estimate the prevalence of SARS-
356 CoV-2 in the community, but also for critical population subgroups such as nursing
357 homes or health care facilities [28].

358
359 This study had some limitations. First, the population included was not representative
360 of the general Togolese population, we actively chose this selection criterion to have a
361 high probability of identifying cases of SARS-CoV-2 infection. Second, we cannot

362 exclude selection bias in our sample due to the recruitment methods. Based on the low
363 prevalence, we did not study the association between prevalence of SARS-CoV-2
364 according to the different sectors. Finally, this study was conducted only in Lomé,
365 capital city of Togo, where 55% of cases of Covid-19 were identified at the time of the
366 survey.

367

368 **Conclusion**

369 In conclusion, the prevalence of the SARS-CoV-2 infection in the capital city among
370 high-risk populations was relatively low two months after the notification of the first
371 case. The low circulation of the virus in high-risk populations could be explained by the
372 various measures taken by the Togolese government. Based on this result,
373 generalized screening of SARS-CoV-2 would be time-consuming, not cost effective
374 and at a high risk of reagent rupture. Therefore, we recommend targeted approach for
375 screening. Targeted screening could include health professionals, airport staff;
376 teachers could also be considered in the event of schools' reopening. Repeated
377 prevalence surveys are needed to refine the strategies to fight against Covid-19 in
378 Togo.

379

380

381

382

383 **List of abbreviations**

384 95% CI: 95% confidence interval; IQR: interquartile range

385 **Acknowledgements**

386 We are thankful to the participants who accepted to participate in this study and the
387 medical students of the 'Faculté des Sciences de la Santé-Université de Lomé' who
388 performed data collection for the study.

389 We hereby also acknowledge the work of the teams of the two laboratories involved in
390 this study, the members of sectorial unit of management of pandemic in the 'Ministère
391 de la Santé et de l'Hygiène Publique' (Ministry of Health), the rapid response teams of
392 health region of Lomé, the staff of Santé Intégrée and the World Health Organization
393 Representative in Togo.

394 Finally, we thank, Alexandra Bitty-Anderson, Abidjan, Côte d'Ivoire; El Houda
395 Roukaya, Alex DeVille and Hannah Wang who edited the English version of this paper.

396

397 **Competing interests**

398 The authors declare that they have no competing interests.

399 **Funding**

400 This work was supported the Government of the Republic of Togo. Dr Rodion KONU
401 was supported by the Agence Nationale de Recherche sur le sida et les hépatites
402 virales (ANRS) in France for his training in Masters of Public Health degree at the
403 'Université de Bordeaux' through the Françoise Barre Sinoussi Fellowship 2019.

404 References

- 405 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J and al. China Novel Coronavirus Investigating
406 and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl
407 J Med. 2020; 382(8):727-733. doi: 10.1056/NEJMoa2001017.

- 408 2. World Health Organization (WHO), Health Emergencies Programmes. Weekly update on
409 COVID-19 –8 May 2020 [Internet]. 2020 [Cited 14/07/2020]. Available from:
410 <https://www.who.int/publications/m/item/weekly-update-on-covid-19---8-may-2020>.

- 411 3. World Health Organization, Regional Office for Africa (OMS/AFRO). Covid 19 : Situation update
412 for the WHO African region, 5 May 2020 [Internet]. 2020 [Cited 14/07/2020]. Available from:
413 [https://apps.who.int/iris/bitstream/handle/10665/331989/SITREP_COVID-](https://apps.who.int/iris/bitstream/handle/10665/331989/SITREP_COVID-19_WHOAFRO_20200506-eng.pdf)
414 [19_WHOAFRO_20200506-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331989/SITREP_COVID-19_WHOAFRO_20200506-eng.pdf).

- 415 4. Richterich, Peter. Severe underestimation of COVID-19 case numbers: effect of epidemic growth
416 rate and test restrictions. medRxiv. 2020 ; 10.1101/2020.04.13.20064220.

- 417 5. Lachmann A, Jagodnik KM, Giorgi FM, Ray F. Correcting under-reported COVID-19 case
418 numbers: estimating the true scale of the pandemic. medRxiv. 2020 ; 2020.03.14.20036178.
419 doi:10.1101/2020.03.14.20036178.

- 420 6. Pan American Health Organization (PAHO), World Health Organization (WHO). Epidemiological
421 Update Novel coronavirus (COVID-19). Washington, D.C.: PAHO/WHO; 2020, 8p.

- 422 7. World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus
423 Disease 2019 (COVID-19). Beijing : WHO ; 2020, 40p.


- 424 8. Elflein J. Rate of COVID-19 testing in most impacted countries worldwide as of May 11, 2020
425 [Internet]. 2020 [Cited 13/04/2020]. Available from:
426 <https://www.statista.com/statistics/1104645/covid19-testing-rate-select-countries-worldwide/>.

- 427 9. US Food and Drug Administration (FDA). Emergency Use Authorizations [Internet]. 2020 [Cited
428 16/05/2020]. Available from: [https://www.fda.gov/medical-devices/emergency-situations-medical-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd)
429 [devices/emergency-use-authorizations#covid19ivd](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd).

- 430 10. République Togolaise, Site d'information officiel du Gouvernement. Coronavirus au Togo :
431 Chiffres mis à jour [Internet]. 2020 [Consulté le 27/04/2020]. Disponible sur :
432 <https://covid19.gouv.tg/>.
- 433 11. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL and al.
434 Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020: NEJMoa2006100. doi:
435 10.1056/NEJMoa2006100.
- 436 12. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R and al. COVID-19
437 Antibody Seroprevalence in Santa Clara County, California. medRxiv 2020.04.14.20062463; doi:
438 <https://doi.org/10.1101/2020.04.14.20062463>.
- 439 13. Hôpitaux Universitaires Genève (HUG). Séroprévalence COVID-19 : Première estimation de la
440 prévalence d'anticorps anti-SARS-CoV-2 IgG dans la population genevoise [Internet]. 2020
441 [consulté le 04/05/2020]. Disponible sur : [https://www.hug-ge.ch/medias/communique-](https://www.hug-ge.ch/medias/communique-presse/seroprevalence-covid-19-premiere-estimation)
442 [presse/seroprevalence-covid-19-premiere-estimation](https://www.hug-ge.ch/medias/communique-presse/seroprevalence-covid-19-premiere-estimation).
- 443 14. National COVID-19 Science Task Force (NCS-TF). The role of serological testing in the COVID-
444 19 response in Switzerland. Berne : NCS-TF ; 2020, 8p.
- 445 15. Bernard SS, Rolland P, Silue Y, Mailles A, Campese C, Simondon A and al. First cases of
446 coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control
447 measures, January 2020. Euro Surveill. 2020; 25(6):2000094. doi: 10.2807/1560-
448 7917.ES.2020.25.6.2000094.
- 449 16. Government of Canada. Risk-informed decision-making for mass gatherings during COVID-19
450 pandemic [Internet]. 2020 [Cited at 04/03/2020]. Available from :
451 [https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/mass-gatherings-risk-assesment.html)
452 [infection/health-professionals/mass-gatherings-risk-assesment.html](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/mass-gatherings-risk-assesment.html).
- 453 17. World Health Organization (WHO). Laboratory testing for coronavirus disease 2019 (COVID-19)
454 in suspected human cases, Interim guidance 2 March 2020 [Internet]. 2020 [Cited 14/07/2020].
455 Available from: [https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-](https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y)
456 [laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y).

- 457 18. Centers for Disease Control and prevention (CDC). Interim Guidelines for Collecting, Handling,
458 and Testing Clinical Specimens for COVID-19 [Internet]. 2020 [Cited 14/07/2020]. Available
459 from: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>.
- 460 19. Vásárhelyi B, Kristóf K, Ostorházi E, Szabó D, Prohászka Z, Merkely B. The diagnostic value of
461 rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus
462 infection. *Orv Hetil.* 2020; 161(20):807-812.
- 463 20. Centre National de référence pour le VIH, Laboratoire de virologie du CHU-SO. Evaluation du
464 test « CLUNGENE RAPID TEST ». In : Ministère togolais de la santé et de l'hygiène publique
465 (MSHP), Direction de la Pharmacie du Médicament et des Laboratoires (DPML). Rapport
466 d'évaluation de la performance des tests de diagnostic sérologique de SARS-CoV-2 soumis au
467 ministère de la santé dans le cadre du processus d'homologation des DMDIV au Togo. Lomé:
468 DPML; 2020. Disponible sur : [https://drive.google.com/file/d/1QqF_Wz-JVrdLREgfVnJ2pGGkkl7-](https://drive.google.com/file/d/1QqF_Wz-JVrdLREgfVnJ2pGGkkl7-e-XY/view?usp=sharing)
469 [e-XY/view?usp=sharing](https://drive.google.com/file/d/1QqF_Wz-JVrdLREgfVnJ2pGGkkl7-e-XY/view?usp=sharing).
- 470 21. République Togolaise, Ministère de la santé et de l'hygiène publique (MSHP). Protocole national
471 de prise en charge des cas de COVID-19. Lomé : MSHP ; 2020, 15p.
- 472 22. Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E and al. Assessment of
473 SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U.S. Cities, March 27-April 15,
474 2020. *MMWR Morb Mortal Wkly Rep.* 2020; 69(17):521-522.
- 475 23. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S and al. Screening of
476 healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19
477 transmission. *medRxiv.* 2020.05.09.20082909; doi:
478 <https://doi.org/10.1101/2020.05.09.20082909>.
- 479 24. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J and al. Estimating the
480 burden of SARS-CoV-2 in France. *Science.* 2020. pii: eabc3517. doi: 10.1126/science.abc3517.
- 481 25. Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY et al. Nasopharyngeal Swabs Are More Sensitive
482 Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load.
483 *Front Med (Lausanne).* 2020;7:334.

- 484 26. Wang X, Tan L, Wang X, Liu W, Lu Y, Cheng L et al. Comparison of nasopharyngeal and
485 oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both
486 specimens simultaneously. *Int J Infect Dis.* 2020; 94:107-109.
- 487 27. Xie J, Ding C, Li J, Wang W, Guo H, Lu Z and al. Characteristics of patients with coronavirus
488 disease (COVID-19) confirmed using an IgM-IgG antibody test. *J Med Virol.* 2020;
489 <https://doi.org/10.1002/jmv.25930>.
- 490 28. World Health Organization (WHO). Population based age stratified seroepidemiological
491 investigation protocol for COVID-19 virus infection. Geneva: WHO; 2020, 15p.
- 492
- 493




494

495

Figure 1: Localization of the participants in the city of Lomé (Togo)

496

497



498

499 **Figure 2: Prevalence of SARS-CoV-2 based on rRT-PCR test and serological test in**
500 **high risk population, Lomé (Togo).**

501

502 **Table 1: Sociodemographic characteristics according to sector of activity, Lomé, Togo**

	Air transport	Police	Informal sector	Health sector	Road transport	Total
	n=212	n=196	n=55	n=370	n=122	N=955
Age (years)						
<36	90 (42.5)	121 (61.7)	17 (30.9)	158 (42.7)	48 (39.3)	434 (45.4)
≥36	122 (57.5)	75 (38.3)	38 (69.1)	212 (57.3)	74 (60.7)	521 (54.6)
Sex						
Men	179 (84.4)	168 (85.7)	34 (61.8)	181 (48.9)	122 (100.0)	684 (71.6)
Women	33 (15.6)	28 (14.3)	21 (38.2)	189 (51.1)	0 (0.0)	271 (28.4)
Nationality						
Togolese	205 (96.7)	196 (100.0)	52 (94.5)	364 (98.4)	119 (97.5)	936 (98.0)
Others	7 (3.3)	0 (0.0)	3 (5.5)	6 (1.6)	3 (2.5)	19 (2.0)
In couple						
No	49 (23.1)	49 (25.0)	10 (18.2)	169 (45.7)	42 (34.4)	319 (33.4)
Yes	163 (76.9)	147 (75.0)	45 (81.8)	201 (54.3)	80 (65.6)	636 (66.6)
Education level						
None	3 (1.4)	0 (0.0)	5 (9.1)	5 (1.4)	11 (9.0)	24 (2.5)
Primary	2 (0.9)	1 (0.5)	4 (7.3)	11 (3.0)	26 (21.3)	44 (4.6)
Secondary	105 (49.5)	143 (73.0)	15 (27.3)	69 (18.6)	68 (55.7)	400 (41.9)
University	102 (48.1)	52 (26.5)	31 (56.4)	285 (77.0)	17 (13.9)	487 (51.0)

503

504 **Table 2: Prevalence of SARS-Cov-2 according to sector of activity in Lomé, Togo**

	Air transport	Police	Informal sector	Health sector	Road transport	Total	95%CI
	n=212	n=196	n=55	n=370	n=122	N=955	
rRT-PCR+	3 (1.4)	1 (0.5)	1 (1.8)	2 (0.5)	0 (0.0)	7 (0.7)	[0.3-1.6]
IgM+	1 (0.5)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.2)	[0.03-0.8]
IgG+	2 (0.9)	0 (0.0)	0 (0.0)	5 (1.4)	1 (0.8)	8 (0.8)	[0.4-1.7]
rRT-PCR+ or IgG+ or IgM+	4 (1.9)	2 (1.0)	1 (1.8)	7 (1.9)	1 (0.8)	15 (1.6)	[0.9-2.6]

505 **+**: Positive **95%CI**: 95% Confidence interval

506

507

508

509

510

511

512 **Table 3: Description of rRT-PCR positive participants (N = 7)**

	Age (years)	Sex	Sector of activity	IgG +	IgM +	Covid-19 symptoms
Participant 1	58	Male	Air transport	No	No	No
Participant 2	52	Male	Air transport	No	No	No
Participant 3	35	Male	Air transport	Yes	No	No
Participant 4	37	Male	Health	No	No	No
Participant 5	30	Female	Health	No	No	Yes*
Participant 6	52	Male	Informal	No	No	No
Participant 7	32	Female	Police	No	No	No

513 ***Presence of fever, headache and myalgia within the past two weeks before enrolment**

514